These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

462 related articles for article (PubMed ID: 28108950)

  • 1. T-cell receptor-engineered T cells for cancer treatment: current status and future directions.
    Ping Y; Liu C; Zhang Y
    Protein Cell; 2018 Mar; 9(3):254-266. PubMed ID: 28108950
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IND-Enabling Studies for a Clinical Trial to Genetically Program a Persistent Cancer-Targeted Immune System.
    Puig-Saus C; Parisi G; Garcia-Diaz A; Krystofinski PE; Sandoval S; Zhang R; Champhekar AS; McCabe J; Cheung-Lau GC; Truong NA; Vega-Crespo A; Komenan MDS; Pang J; Macabali MH; Saco JD; Goodwin JL; Bolon B; Seet CS; Montel-Hagen A; Crooks GM; Hollis RP; Campo-Fernandez B; Bischof D; Cornetta K; Gschweng EH; Adelson C; Nguyen A; Yang L; Witte ON; Baltimore D; Comin-Anduix B; Kohn DB; Wang X; Cabrera P; Kaplan-Lefko PJ; Berent-Maoz B; Ribas A
    Clin Cancer Res; 2019 Feb; 25(3):1000-1011. PubMed ID: 30409823
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TCR-engineered T cells to treat tumors: Seeing but not touching?
    Debets R; Donnadieu E; Chouaib S; Coukos G
    Semin Immunol; 2016 Feb; 28(1):10-21. PubMed ID: 26997556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improving the efficacy and safety of engineered T cell therapy for cancer.
    Shi H; Liu L; Wang Z
    Cancer Lett; 2013 Jan; 328(2):191-7. PubMed ID: 23022475
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase 1 trial of NY-ESO-1-specific TCR-engineered T-cell therapy combined with a lymph node-targeting nanoparticulate peptide vaccine for the treatment of advanced soft tissue sarcoma.
    Ishihara M; Nishida Y; Kitano S; Kawai A; Muraoka D; Momose F; Harada N; Miyahara Y; Seo N; Hattori H; Takada K; Emori M; Kakunaga S; Endo M; Matsumoto Y; Sasada T; Sato E; Yamada T; Matsumine A; Nagata Y; Watanabe T; Kageyama S; Shiku H
    Int J Cancer; 2023 Jun; 152(12):2554-2566. PubMed ID: 36727538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CRISPR/Cas9-medaited knockout of endogenous T-cell receptor in Jurkat cells and generation of NY-ESO-1-specific T cells: An in vitro study.
    Safarzadeh Kozani P; Shokrgozar MA; Evazalipour M; Roudkenar MH
    Int Immunopharmacol; 2022 Sep; 110():109055. PubMed ID: 35853277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How does TCR-T cell therapy exhibit a superior anti-tumor efficacy.
    Yang D; Duan Z; Yuan P; Ding C; Dai X; Chen G; Wu D
    Biochem Biophys Res Commun; 2023 Dec; 687():149209. PubMed ID: 37944471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Emerging World of TCR-T Cell Trials Against Cancer: A Systematic Review.
    Zhang J; Wang L
    Technol Cancer Res Treat; 2019 Jan; 18():1533033819831068. PubMed ID: 30798772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced Cancer Immunotherapy by Chimeric Antigen Receptor-Modified T Cells Engineered to Secrete Checkpoint Inhibitors.
    Li S; Siriwon N; Zhang X; Yang S; Jin T; He F; Kim YJ; Mac J; Lu Z; Wang S; Han X; Wang P
    Clin Cancer Res; 2017 Nov; 23(22):6982-6992. PubMed ID: 28912137
    [No Abstract]   [Full Text] [Related]  

  • 10. The recent advancement of TCR-T cell therapies for cancer treatment.
    Zhao X; Shao S; Hu L
    Acta Biochim Biophys Sin (Shanghai); 2024 May; 56(5):663-674. PubMed ID: 38557898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recognition of NY-ESO-1+ tumor cells by engineered lymphocytes is enhanced by improved vector design and epigenetic modulation of tumor antigen expression.
    Wargo JA; Robbins PF; Li Y; Zhao Y; El-Gamil M; Caragacianu D; Zheng Z; Hong JA; Downey S; Schrump DS; Rosenberg SA; Morgan RA
    Cancer Immunol Immunother; 2009 Mar; 58(3):383-94. PubMed ID: 18677478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploiting natural killer group 2D receptors for CAR T-cell therapy.
    Demoulin B; Cook WJ; Murad J; Graber DJ; Sentman ML; Lonez C; Gilham DE; Sentman CL; Agaugue S
    Future Oncol; 2017 Aug; 13(18):1593-1605. PubMed ID: 28613086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reprogramming of IL-12 secretion in the PDCD1 locus improves the anti-tumor activity of NY-ESO-1 TCR-T cells.
    Kim S; Park CI; Lee S; Choi HR; Kim CH
    Front Immunol; 2023; 14():1062365. PubMed ID: 36793716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. T-cell adoptive immunotherapy using tumor-infiltrating T cells and genetically engineered TCR-T cells.
    Ikeda H
    Int Immunol; 2016 Jul; 28(7):349-53. PubMed ID: 27127191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rebalancing immune specificity and function in cancer by T-cell receptor gene therapy.
    Udyavar A; Geiger TL
    Arch Immunol Ther Exp (Warsz); 2010 Oct; 58(5):335-46. PubMed ID: 20680493
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blockade of Programmed Death 1 Augments the Ability of Human T Cells Engineered to Target NY-ESO-1 to Control Tumor Growth after Adoptive Transfer.
    Moon EK; Ranganathan R; Eruslanov E; Kim S; Newick K; O'Brien S; Lo A; Liu X; Zhao Y; Albelda SM
    Clin Cancer Res; 2016 Jan; 22(2):436-47. PubMed ID: 26324743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors.
    Zhang E; Gu J; Xu H
    Mol Cancer; 2018 Jan; 17(1):7. PubMed ID: 29329591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical studies show that Co-STARs combine the advantages of chimeric antigen and T cell receptors for the treatment of tumors with low antigen densities.
    Mog BJ; Marcou N; DiNapoli SR; Pearlman AH; Nichakawade TD; Hwang MS; Douglass J; Hsiue EH; Glavaris S; Wright KM; Konig MF; Paul S; Wyhs N; Ge J; Miller MS; Azurmendi P; Watson E; Pardoll DM; Gabelli SB; Bettegowda C; Papadopoulos N; Kinzler KW; Vogelstein B; Zhou S
    Sci Transl Med; 2024 Jul; 16(755):eadg7123. PubMed ID: 38985855
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor-Resident Dendritic Cells and Macrophages Modulate the Accumulation of TCR-Engineered T Cells in Melanoma.
    Hotblack A; Holler A; Piapi A; Ward S; Stauss HJ; Bennett CL
    Mol Ther; 2018 Jun; 26(6):1471-1481. PubMed ID: 29628306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. T cell receptor repertoire usage in cancer as a surrogate marker for immune responses.
    Schrama D; Ritter C; Becker JC
    Semin Immunopathol; 2017 Apr; 39(3):255-268. PubMed ID: 28074285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.